Biovendor Group Presents CLIA Solution for Complex Diagnostics at MEDICA 2022
Posted on 16 Nov 2022
BioVendor Group (Brno, Czech Republic) is presenting its growing CLIA portfolio of parameters or Microblot Array, multiplex diagnostics in microtiter plate format, alongside fastGEN, a new technology for examination of the mutation status of oncomarkers, and microRNA, a complex solution for short RNA biomarkers, at MEDICA 2022.
Microblot–Array (MBA) is a new generation of unique, immunoblot array in a microtiter plate format that is designed for efficient multiplex diagnostics, enabling the simultaneous detection of multiple markers which can save time and lower costs. The technology eliminates the limited capacity of traditional BLOT strips and opens the opportunity for high throughput testing. Processing can be performed automatically using open ELISA analyzers. The evaluation is performed by the Microblot–Array Reader and software (SW). Results can be exported in various formats and the system can be connected to LIS.
BioVendor’s new technology fastGEN is intended for examination of the mutation status of oncomarkers in samples. The technology is based on ultra-deep sequencing of short amplicons obtained by a single polymerase chain reaction with special tagged hybrid primers. The fastGEN technology is simple, ultra-sensitive, specific and effective - it is perfectly adapted to diagnostics and offers new advantages for clinical material. BioVendor offers user-friendly diagnostic kits with software solution for KRAS, NRAS, BRAF, EGFR, IDH 1/2 and POLE genes with excellent analytical parameters and extremely fast processing. The company’s GENOVESA software fastGEN module is a cloud all-in-one solution for the analysis of raw data (FASTQ files) with technical and application support.
microRNA (miRNA) represent the most progressive group of diagnostic and prognostic biomarkers. A wide range of expression panels and targeted measurements for individual miRNAs on the principle of immunoblot or qPCR opens up new possibilities for the diagnosis of serious pathologies. Monitoring miRNA levels can be used to describe the molecular mechanism or early diagnosis of various pathologies and to identify their stages. BioVendor’s diagnostic panels manage to determine the current risks to the patient's health condition. Early diagnosis and correctly set treatment are key to the successful prognosis of the patient, and in both cases miRNAs are promising biomarkers.
Related Links:
BioVendor Group
